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ABSTRACT
Objective: To evaluate postganglionic autonomic involvement in multiple system atrophy (MSA).
Methods: We quantified sudomotor innervation in skin biopsy of 29 patients with MSA (19 male
and 10 female; age 60.0 6 7.7 years) and 29 age- and sex-matched healthy subjects. Samples
were obtained from thigh and leg and, in 20 out of the 29 cases, also from fingertip. Dysauto-
nomic complaints were evaluated by SCOPA-AUT, a self-administered questionnaire. Sudomotor
function was evaluated in a subgroup of patients by the silastic imprint test. Skin samples were
processed by indirect immunofluorescence using pan-neuronal and selective cholinergic markers.
Total length of sudomotor nerves was measured on digital confocal images using a semiauto-
mated morphometric approach.
Results: Measurements of sudomotor nerve density (total length of nerve per volume of glandular
tissue) favorably correlated to values obtained using a stereologic unbiased method. Sudomotor
nerve density was lower in patients compared to controls in all the examined sites (0.9 6 0.2 vs
1.9 6 0.4 nm/mm3, p , 0.001, in fingertip; 0.7 6 0.2 vs 1.9 6 0.5 nm/mm3, p , 0.001, in thigh;
0.6 6 0.2 vs 1.8 6 0.4 nm/mm3, p , 0.001, in leg).
Conclusions: Our data support the hypothesis that postganglionic impairment occurs in MSA and
may contribute with the coexisting degeneration of central structures to the development of dys-
autonomic disorders in this condition. Neurology® 2014;82:1–7
GLOSSARY
ColIV 5 collagen IV; ENF 5 epidermal nerve fiber; GDS-UMSARS 5 global disability score of the Unified MSA Rating Scale;
ICC 5 intraclass correlation coefficient;MBFB 5 Microbrightfield Bioscience; MSA 5 multiple system atrophy; PD 5 Parkinson
disease; PGP 5 protein gene product; SCOPA-AUT 5 Scales for Outcomes in Parkinson’s disease–Autonomic; SIT 5 silastic
imprint test; VIP 5 vasoactive intestinal peptide.
Multiple system atrophy (MSA) is a neurodegenerative disease characterized by the progressive
involvement of multiple neurologic domains. According to the most recent guidelines,1 auto-
nomic dysfunction is necessary for a premortem diagnosis. In addition to orthostatic hypoten-
sion and genitourinary dysfunction, sudomotor failure is a common finding.2 Despite its clinical
relevance, the anatomic sites responsible for dysautonomia in MSA remain disputed; although
preganglionic involvement is considered the cause,3 abnormalities of postganglionic sympathetic
neurons have also been suggested.4 Determining whether or not postganglionic neurons are
involved in MSA is not a minor issue. Actually, postganglionic involvement in patients with
early extrapyramidal symptoms is thought to help differentiate between Parkinson disease (PD)
and MSA.5 However, attempts aimed at confirming or disconfirming the involvement of post-
ganglionic fibers in MSA have been inconclusive.6,7
Morphometric analysis of autonomic nerves residing in the skin is a promising investigative
tool.8 Cutaneous annexes are abundantly innervated by postganglionic sympathetic autonomic
fibers.9 These nerves are easily accessible through a minimally invasive punch biopsy.10 Current
*These authors contributed equally to this work.
From the Neurology Division (V.P., M.N., G.C., A.S., B.L.), “Salvatore Maugeri” Foundation, Medical Center of Telese Terme (BN); the Department of
Neurosciences and Reproductive and Odontostomatologic Sciences (F.M., R.I., A.D.R., G.D.M., L.S.), University “Federico II” of Naples, Italy; the Department
of Neurology (M.M.S.), University of Minnesota, Minneapolis; and the Center for Neurodegenerative Diseases (M.T.P.), University of Salerno, Italy.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
© 2014 American Academy of Neurology 1
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
 Published Ahead of Print on May 16, 2014 as 10.1212/WNL.0000000000000518
imaging technology allows for high-resolution
3D digital images of cutaneous annexes that
are suitable for morphometric evaluation.
We quantified sweat gland innervation in
skin samples from patients with MSA and
from healthy subjects in an attempt to assess
the postganglionic portion of the sudomotor
pathway. We utilized a new method of quan-
tification with semiautomated tracking of
nerve fibers through 3D images using a soft-
ware that determines nerve trajectories in the
x, y, and z planes and subsequently traces com-
plex structures.11 To validate this procedure,
we compared the results with measurements
from standard unbiased stereology.12
METHODS Subjects. Twenty-nine patients (19 men, 10
women; age 60.06 7.7 years; disease duration 2.76 1.3 years) were
enrolled consecutively from 2006 to 2012 with probable (21 patients)
or possible (8 patients) MSA, according to the second consensus
statement on the diagnosis ofMSA.1 The phenotype was characterized
by prevalently cerebellar features in 16 and by parkinsonian signs in
the remaining 13 patients. Disease severity was evaluated using
the global disability score of the Unified MSA Rating Scale13
(GDS-UMSARS). Clinical involvement of autonomic domains
was evaluated using the Scales for Outcomes in Parkinson’s disease–
Autonomic (SCOPA-AUT), a self-administered questionnaire
developed to assess autonomic symptoms in patients with PD.14
Recently this questionnaire has proved reliable for the screening of
autonomic symptoms in MSA.15 Patients’ clinical evolution was
followed between 2006 and 2012. Five out of 8 patients, classified
at enrollment as possible MSA, at the end of follow-up fulfilled
the criteria for probable MSA. Average GDS-UMSARS score was
2.6 6 1.3 at baseline and 4.4 6 1.0 at follow-up. Demographics
along with clinical data are reported in table e-1 on the Neurology®
Web site at Neurology.org.
At the time of enrollment, all subjects underwent clinical and
electrophysiologic evaluation and performed skin biopsies from 3
body sites: proximal thigh, distal leg, and fingertip, except for 9
patients who opted out of the fingertip biopsy. Twenty-nine
age- and sex-matched healthy subjects were also included in the
study as controls for morphologic study. Age differences#2 years
have been allowed in order to compose the case/control pairs. In
12 pairs out of 29, age differences were greater than 0.
At enrollment, patients also completed the SCOPA-AUT
questionnaire to assess autonomic involvement. The question-
naire is composed of 23 items exploring the occurrence of symp-
toms related to the function of 6 different autonomic domains.
For each item, the score ranges from 0 to 3. We assumed a
domain was involved if at least 1 item obtained a score of 2.
Immunohistochemistry and image acquisition. Skin
samples (3-mm punch) were fixed overnight in Zamboni
solution (picric acid and paraformaldehyde) and then cryo-
protected in 20% sucrose phosphate-buffered saline. Fifty-
micrometer-thick sections were cut using a freezing sliding
microtome (Leica 2000R; Nussloch, Germany) and labeled
for indirect immunofluorescence according to a previously
published procedure.16
Using a nonlaser confocal microscope (AxioImagerM2 with
Apotome2; Zeiss, Göttingen, Germany), 3D digital images of
sweat glands were acquired using a 203 objective (Zeiss EC Plan
NeoFluar 203/0.5). To avoid nonrepresentative sweat gland
fragments, only sweat glands at least 25 mm thick were included
in quantifications. A minimum of 4 sweat glands per site were
identified and imaged: 2 marked with the marker for cholinergic
fibers vasoactive intestinal peptide (VIP; SC25347, 1:300 dilu-
tion; Santa Cruz Biotechnology, Dallas, TX) and 2 with the pan-
neural marker protein gene product 9.5 (PGP 9.5; E3344, 1:400
dilution; Biospring, Frankfurt am Main, Germany). For sweat
gland volume quantification, imaging was acquired using markers
for collagen IV (ColIV; MAB1910, 1:800 dilution; Chemicon,
Billerica, MA) and Ulex Europaeus agglutinin I (B1065, 1:100
dilution; Vector, Burlingame, CA), in addition to the specific
neural marker.
Quantification of sudomotor nerves. Semiautomated
morphometry. Sudomotor nerve length density (nm/mm3) was
calculated using the nerve tracing module Autoneuron, a part of
Neurolucida software (Microbrightfield Bioscience [MBFB],
Williston, VT). Briefly, within the 3D confocal image stack of
nerve-associated immunoreactivity, nerve fibers were identified
with a series of single voxels. The software identified the voxels
with the highest probability of being nerve-associated. It then
traced the nerve trajectory that was morphologically compatible
with the antibody and within the specified parameters of x, y, and
z planes (figure 1, A, B, D, and F). The software was set up to
only trace continuous, linear structures at least 10 mm in length
with a defined thickness (between 0.8 and 2.5 mm for PGP
staining and between 0.8 and 2.0 mm for VIP staining). Such
rules, based on the characteristics of nerve-associated staining,
exclude non-nerve-related fluorescence from quantification. After
completion of the 3D tracing, the total length was recorded and
later converted to a length density after calculating the volume of
the imaged gland (figure 1H). Sweat gland volume was calculated
by manually tracing the outside contour on alternate optical
sections of composite confocal images showing PGP 9.5, ColIV,
and Ulex; this procedure ensured that no portions of the gland
were accidently excluded due to denervated tubules. To verify the
repeatability of the method, 2 investigators blinded to disease or
control state quantified sudomotor innervation in 40 3D confocal
images of sweat glands, 20 with each neural stain (VIP and
PGP 9.5).
Unbiased stereology. To verify the accuracy of the semiauto-
mated nerve tracing method, a group of 40 sweat glands were re-
quantified by adopting unbiased stereology using the software
StereoInvestigator (MBFB). Nerve length was estimated using
the isotropic spherical probe,17,18 which estimates total length
by counting the intercepts between nerves and a virtual spherical
probe systematically and randomly distributed at known distan-
ces within the tissue (figure 1, A, C and E). Sweat gland volume
was estimated with the Cavalieri method (figure 1G).19
To compare autonomic and somatic involvement in patients,
the linear density of epidermal nerve fibers (ENFs) was quantified
in all skin samples using standard procedures.10
Functional evaluation. In a subgroup of 10 patients, a func-
tional sudomotor evaluation was performed using the silastic
imprint test20 (SIT) to calculate the density of sweat glands acti-
vated by iontophoresis of 1% pilocarpine. Results were compared
with laboratory age- and sex-stratified normative dataset.
Statistical analysis. Numerical data are presented as mean 6
SD. We assessed the distribution of our data using the Shapiro-
Wilk test. Since 4 out of 9 series of data were not normally
distributed, we used the Mann-Whitney test to evaluate
differences between control subjects and patients, and between
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patients with different phenotypes. Bonferroni correction for
multiple testing was applied and a p value , 0.05 was
considered significant.
Intraclass correlation coefficient (ICC) between measures per-
formed on the same gland sample by different operators was used
to assess interrater repeatability. Bland-Altman analysis was used
to assess agreement between the 2 methods of sudomotor nerve
quantification (semiautomated morphometry and unbiased stere-
ology). Pearson regression was used to assess the correlation
between morphologic data on one side and functional data,
age, disease duration, autonomic involvement, and disease sever-
ity on the other side.
Standard protocol approvals, registrations, and patient
consents. All participants signed a written informed consent and
the study was approved by the institutional ethical committee.
RESULTS According to scores on the self-
administered SCOPA-AUT questionnaire (table e-1),
among different autonomic domains, the urinary was
the more frequently (26 out of 29 patients) affected
and the pupillomotor the less frequently (7 out of 29
patients) affected. The thermoregulatory domain was
involved in 14 out of 29 patients. Average
cumulative SCOPA-AUT score was 18.2 6 3.8.
Morphologic data. Bland-Altman analysis (figure e-1)
showed a mean difference between the 2 methods of
nerve quantification greater than zero (0.39 nm/mm3
with a SD of 0.74 nm/mm3) but adequate to appreciate
the differences that we observed between patients and
controls. Moreover, semiautomated measures of sudo-
motor nerve density performed on the same subset of
40 glands by 2 operators showed a good repeatability of
the procedure (ICC 5 0.9, p , 0.001).
Using semiautomated morphometry, we quanti-
fied sudomotor innervation of 865 sweat glands:
420 from 29 patients with MSA (232 with PGP
9.5 and 188 with VIP) and 445 from 29 control sub-
jects (243 with PGP 9.5 and 202 with VIP). Quanti-
tative data are summarized in table 1.
Sudomotor nerve density was lower in MSA com-
pared to control subjects (p , 0.001). This finding
was evident at the thigh and distal leg using both the
pan-neuronal marker PGP 9.5 and the specific cho-
linergic marker VIP (figure 2). At the fingertip, sudo-
motor nerve fiber loss was significant (p , 0.001)
only with the cholinergic marker, whereas no statis-
tical significance (p 5 0.7) was attained using PGP
9.5. We found a non-length-dependent loss (p ,
0.05) of ENFs in patients with MSA in all the exam-
ined sites compared to control subjects.
Sudomotor functional evaluation. SIT showed a reduc-
tion (p , 0.05) of the density of sweat glands acti-
vated by direct pharmacologic stimulation in patients
with MSA (45.16 24.3 sweat glands/cm2) compared
to controls (102.66 19.8 sweat glands/cm2), and the
loss correlated (p , 0.05, r 5 0.56) with sudomotor
nerve fiber density at the distal leg.
Figure 1 Methods used to quantify sudomotor innervation
(A) Projection of a 3D triple-stained (protein gene product [PGP] 9.5, collagen IV [ColIV], and Ulex)
confocal image of a sweat gland. Semiautomatedmethod (red path): the software identifieswithin
the z-series stack of nerve-associated immunoreactivity (B) the voxelswith the highest probability
of being nerve-associated (D). Then, starting from these voxels, the software traces the nerve tra-
jectory (F) and measures its total length. The total length is reported as a length density (nm/mm3)
after calculating the volume of the imaged gland interpolated in 3D (H) by manually tracing its
outside contour on the optical sections of the composite confocal image. Unbiased stereology
method (green path): the software places virtual spherical probes systematically and randomly
within the tissue (C). Then the operator selects all the intercepts between nerve fibers and the
profile of the probe through the z-stack (E) before obtaining the unbiased estimation of total nerve
length. The volume of the gland is calculated with the Cavalieri method (G).
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Sudomotor nerve loss did not correlate (p. 0.05)
with disease severity as expressed by the GDS-
UMSARS, with clinical autonomic involvement,
with age, or with disease duration, regardless of the
site (thigh, leg, or fingertip) and the nerve marker
(PGP or VIP). All patients, even those with less than
a year disease duration, showed an abnormal sweat
gland nerve fiber density in at least 2 of the 3 exam-
ined sites, with no difference between cerebellar and
parkinsonian phenotypes (p . 0.05) or between pa-
tients with and without clinically appreciable thermo-
regulatory disturbances (p. 0.05). The loss observed
at proximal and distal sites on the leg was comparable
(about 60% loss compared to control values).
DISCUSSION This study demonstrates histologic
involvement of postganglionic autonomic fibers in
MSA by showing a reduced innervation of sweat
glands. The degree of sudomotor denervation was
comparable at proximal and distal sites of the lower
limb, suggesting a ganglionopathy rather than a
length-dependent neuropathic process. Autonomic
nerve loss did not correlate with clinical impairment
as assessed by the SCOPA-AUT questionnaire, nor
were we able to demonstrate a more severe sudomotor
denervation in patients with a clinical impairment of
thermoregulation. We observed a correlation between
sudomotor nerve loss and functional sudomotor
impairment, however.
This is not the first attempt at quantifying nerves of
dermal annexes, but the complexity of these structures
makes accurate quantification a challenging task.
Methods based on semiquantitative evaluations21 or
on the quantification of nerve-related fluorescence
(based on the arbitrary selection of a brightness thresh-
old)22 seem unreliable as they are incapable of detecting
small variations in nerve density. More accurate meas-
urements, following validation with stereologic meth-
ods, have been successfully used to demonstrate
sudomotor denervation in other pathologies.8 We used
a semiautomated method previously shown to be reli-
able and reproducible in the quantification of the com-
plex mucosal nerves in patients with idiopathic chronic
childhood constipation.23
The agreement between the results from our 2
independent operators was expected as, within a con-
focal image stack, nerve tracking is an automated pro-
cess and outlining of a sweat gland is the only
operator-dependent variable. We verified our results
using stereology and found them to agree with length
density estimates.
Quantification of a single sweat gland using the
semiautomated method took approximately 10 mi-
nutes; this included optical field selection, acquiring
digital images, and completing the nerve tracing. It
was much more time-consuming (about 45 minutes)
Table 1 Morphologic data
Age, y
Fingertip Thigh Leg
SNF (PGP) SNF (VIP) ENF SNF (PGP) SNF (VIP) ENF SNF (PGP) SNF (VIP) ENF
MSA 60.0 (7.7) 1.8 (0.4) 0.9 (0.2) 2.6 (2.3) 1.4 (0.4) 0.7 (0.2) 12.9 (3.3) 1.4 (0.4) 0.6 (0.2) 7.3 (4.4)
Controls 60.0 (8.0) 2.0 (0.4) 1.9 (0.4)a 7.9 (2.2)a 1.9 (0.3)a 1.9 (0.5)a 19.6 (4.0)a 2.1 (0.4)a 1.8 (0.4)a 15.6 (2.9)a
Abbreviations: ENF 5 epidermal nerve fibers; MSA 5 multiple system atrophy; PGP 5 protein gene product; SNF 5 sudomotor nerve fibers; VIP 5
vasoactive intestinal peptide.
Density of SNF expressed as nm/mm3, density of ENF expressed as number/linear mm. All data are expressed as mean (SD).
ap , 0.001 (Mann-Whitney test, Bonferroni-corrected).
Figure 2 Sudomotor innervation in multiple system atrophy and control
Confocal images of skin from a thigh show sweat gland innervation in a control subject
(A, C) and a patient (B, D). The loss of sudomotor nerve fibers is evident using both the
pan-neuronal marker protein gene product (PGP) 9.5 (B compared to A) and the selective cholin-
ergic marker vasoactive intestinal peptide (D compared to C). 203 images. Scale bar is 100 mm.
COLIV 5 collagen IV.
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to complete the analysis of one sweat gland using
stereology.
MSA is characterized pathologically by cell loss,
gliosis, and glial cytoplasmic inclusions localized in
several structures of CNS. Specifically, Lewy pathol-
ogy and cell loss have been demonstrated in multiple
autonomic nuclei such as the intermediolateral col-
umn of the spinal cord,24 the ventrolateral portion
of the intermediate reticular formation,25 the dorsal
motor nucleus of vagus,26 ambiguus nucleus,27 raphe
nucleus,28 arcuate nucleus,29 and locus ceruleus.30
Therefore, dysautonomia is usually considered sec-
ondary to the involvement of the preganglionic struc-
tures even though correlation between cell loss and
the clinical degree of autonomic impairment is often
unsatisfactory.31
It is assumed that sweating abnormalities in MSA
are also preganglionic, resulting from the degeneration
of central components of the sudomotor pathway.5
The often-reported lack of postganglionic involvement
mainly stems from comparisons to PD, where a more
severe involvement of postganglionic sympathetic car-
diac innervation, as evaluated by MIBG myocardic
scintigraphy, is apparent.32 Although relatively spared
compared to PD, myocardic sympathetic innervation
is impaired in patients with MSA when compared to
healthy control subjects.33
MIBG scintigraphy was not included in the diag-
nostic protocol of our patients; therefore, we could
not compare our data of cutaneous postganglionic
denervation with the degree of adrenergic postgangli-
onic cardiac denervation. However, our functional
and morphologic findings are in agreement with other
experimental data that suggest postganglionic involve-
ment of the sudomotor pathway in MSA. In fact, an
impairment of sudomotor postganglionic fibers has
been demonstrated by a reduced sudomotor response
after both direct34 and axon reflex–mediated35 pharma-
cologic stimulation. Moreover, postganglionic sympa-
thetic denervation in MSA has been demonstrated in
other structures such as the bladder internal sphinc-
ter,36 and Lewy bodies spotted in sympathetic ganglia
of patients with MSA37 provide convincing pathologic
evidence for the involvement of postganglionic sympa-
thetic neurons.
We previously reported on peripheral nervous sys-
tem involvement in diseases characterized mainly by
CNS degeneration.38 A few studies tried to demon-
strate an impaired peripheral autonomic system in
MSA by quantifying sudomotor nerves. These studies
were inconclusive, possibly because of the relatively
small number of subjects examined.39 Recently, a loss
of sudomotor nerves has been reported in skin biop-
sies from 3 out of 8 patients with MSA.21 The authors
suggest that the postganglionic impairment may be
due to trans-synaptic cell death in patients with long-
standing disease. Our findings do not support this
hypothesis. We found no correlation between sudo-
motor denervation and disease duration. Sudomotor
denervation was present even in patients with less than
1 year of disease duration. Patients also demonstrated a
coexisting, severe, generalized, and non-age-related
ENF loss, for which a trans-synaptic degenerative
mechanism is not plausible. Our findings suggest that
the involvement of peripheral somatic and autonomic
fibers may be part of the pathophysiology of MSA
rather than a late secondary phenomenon.
Our MSA patient population displayed a sudomo-
tor denervation that was evident at the lower limbs
regardless of the neural marker used. At the fingertip,
a more innervated and vascularized site, sweat glands
displayed nerve fiber loss only with the specific cho-
linergic marker VIP. This finding supports previous
observations of a loss of immunoreactivity that pre-
cedes the actual nerve loss in neurodegenerative
processes.40
We demonstrated sudomotor postganglionic
denervation in patients with MSA using a semiauto-
mated quantitative method. The postganglionic
involvement may be part of the disease, contributing
with the coexisting degeneration of central structures
to the development of the variety of autonomic symp-
toms depicted in MSA.
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